Image For Activity Cover
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma (JACC: CardioOncology November 2022)
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma
This study sought to assess the prevalence of TT in RCC, its current management, and its association with venous thromboembolism (VTE), arterial thromboembolism (ATE), major bleeding (MB), and mortality.

JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC

Authors
Fleur H.J. Kaptein, MD
Frederikus A. Klok, MD, PhD

Important Dates

Date of Release: November 15, 2022
Term of Approval/Date of CME/MOC/ECME Expiration: November 14, 2023

Summary
Availability: On-Demand
Expires on Nov 14, 2023
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By